Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-26481585 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| JNJ-26481585 | DRUG | - |
Inclusion Criteria: * Confirmed solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective * Performance status (based on the Eastern Cooperative Oncology Group assessments) of \<= 2 * Life expectan...
Top 20 of 70 competitors
JNJ-26481585 is an investigational small molecule being studied for the treatment of lymphoma and advanced solid malignancies. It is in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being evaluated for safety and dosing in clinical trials.
JNJ-26481585 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 1 clinical development for oncology indications, including lymphoma.
JNJ-26481585 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies. A Phase 1 trial has been completed, and the drug remains under investigation for safety and dosing in patients with advanced solid malignancies and lymphoma.
JNJ-26481585 has one completed clinical trial, identified as NCT00677105. This was a Phase 1, open-label, uncontrolled safety and dose-finding study conducted in the United Kingdom, enrolling 92 patients with advanced solid malignancies and lymphoma. The trial is no longer active.
JNJ-26481585 is the primary name for this investigational compound. No alternative names have been established in the available clinical trial data. It is a small molecule being studied for its potential use in oncology, specifically for lymphoma and advanced solid tumors.